Back to the Top
The following message was posted to: PharmPK
Brazilian legislation currently does not require bioequivalence
studies for drugs that are not intended for systemic absorption.
Classical examples are mebendazole, albendazole and tiabendazole.
The point is that if those drugs have indications such as treatment
of neurocysticercosis, that implies a systemic absorption and all PK
issues. However there's currently a gap that can be exploited.
I'm collecting data on how this issue is dealt with by other
regulatory agencies such as FDA/EMEA.
If anyone has any directions on this, I'd appreciate.
Thanks in advance.
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Exemption of BE studies in cases of no systemic absorption" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (firstname.lastname@example.org)